BTIG analyst Mark Massaro reiterated a Buy rating on Guardant Health (GH – Research Report) yesterday and set a price target of $60.00. The ...

As reproductive health access becomes increasingly restricted across the country, expanding Washington’s law that protects ...

This review discusses the current state of multicancer early detection tests, the role of machine learning in their ...

Guardant Health has an expanding pipeline that could significantly boost its future market potential. Check out my ...

In a report released today, Luke Sergott from Barclays maintained a Buy rating on Guardant Health (GH – Research Report), with a price target ...